NF1 Inactivation Revs Up Ras in Adult Acute Myelogenous Leukemia

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2010 Jul 1

PMID 20587590

Citations 7

Authors

Ann Mullally

Benjamin L Ebert

Affiliations

Soon will be listed here.

Abstract

Mutations in the Ras pathway are common in myeloid malignancies. NF1, a tumor suppressor and negative regulator of Ras, is inactivated in a subset of adult acute myelogenous leukemia (AML) cases. Loss of NF1 function sensitizes cells to inhibition of mammalian target of rapamycin (mTOR), a downstream effector of Ras activation, highlighting a potential therapeutic opportunity for some AML patients.

Citing Articles

Neurofibromatosis Symptom-Lacking B-Cell Lineage Acute Lymphoblastic Leukemia with Only an Gene Pathogenic Variant.

Kim Z, Lee J Diagnostics (Basel). 2023; 13(8).

PMID: 37189588 PMC: 10138240. DOI: 10.3390/diagnostics13081486.

The Impact of PI3-kinase/RAS Pathway Cooperating Mutations in the Evolution of -rearranged Leukemia.

Esposito M Hemasphere. 2019; 3(3):e195.

PMID: 31723831 PMC: 6746018. DOI: 10.1097/HS9.0000000000000195.

CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition.

Post J, Hami N, Mertens A, Elfrink S, Bos J, Snippert H Oncotarget. 2019; 10(14):1440-1457.

PMID: 30858928 PMC: 6402720. DOI: 10.18632/oncotarget.26677.

mTORC signaling in hematopoiesis.

Wang X, Chu Y, Wang W, Yuan W Int J Hematol. 2016; 103(5):510-8.

PMID: 26791377 DOI: 10.1007/s12185-016-1944-z.

Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?.

Peterson J, Aggarwal N, Smith C, Gollin S, Surti U, Rajkovic A Oncotarget. 2015; 6(22):18845-62.

PMID: 26299921 PMC: 4662459. DOI: 10.18632/oncotarget.4586.